Cargando…

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

With immunotherapy innovations for cancer treatment, in particular chimeric antigen receptor (CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage their toxicities are required. Anti-CD19 CAR T-cell therapy has revolutionized the treatment of relapsed/refractory pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riegler, Lara L, Jones, Gavin P, Lee, Daniel W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400118/ https://www.ncbi.nlm.nih.gov/pubmed/30880998 http://dx.doi.org/10.2147/TCRM.S150524

Ejemplares similares

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
por: Siegler, Elizabeth L., et al.
Publicado: (2020)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
por: Hu, Yongxian, et al.
Publicado: (2016)

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
por: Zhang, Lina, et al.
Publicado: (2021)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
por: Guo, Hanfei, et al.
Publicado: (2022)

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
por: Lai, Xun, et al.
Publicado: (2020)

Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report
por: Zhang, Lan, et al.
Publicado: (2022)

Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion
por: Bottari, Gabriella, et al.
Publicado: (2020)

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?
por: Dave, Prashil, et al.
Publicado: (2021)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
por: Park, Jae H, et al.
Publicado: (2018)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
por: Hong, Fei, et al.
Publicado: (2021)

Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
por: Shima, Haruko, et al.
Publicado: (2021)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy
por: Nakamura, Naokazu, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Inoue, Yu, et al.
Publicado: (2023)

Cytokine release syndrome: grading, modeling, and new therapy
por: Liu, Delong, et al.
Publicado: (2018)

Current Advances and Hurdles in Chimeric Antigen Receptor Technology
por: McComb, Scott, et al.
Publicado: (2020)

Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
por: Marei, Hany E., et al.
Publicado: (2021)

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
por: Wang, Li-Xin, et al.
Publicado: (2018)

Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia
por: Shima, Haruko, et al.
Publicado: (2022)

Is Chimeric Antigen Receptor T-cell Therapy the Future of Autoimmunity Management?
por: Tahir, Amber
Publicado: (2018)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
por: Du, Mengyi, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Current and future perspectives of chimeric antigen receptors against glioblastoma
por: Zhang, Josephine, et al.
Publicado: (2022)

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report: Erratum
Publicado: (2018)

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
por: Liu, Xuan, et al.
Publicado: (2020)

Toxicity of Chimeric Antigen Receptor T Cells and its Management
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome
por: Jiang, Ying, et al.
Publicado: (2022)

Sequential control of myeloid cell proliferation and differentiation by cytokine receptor-based chimeric antigen receptors
por: Nakajima, Kyoko, et al.
Publicado: (2022)

Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report
por: Zi, Fu Ming, et al.
Publicado: (2021)

Cytokine Release Syndrome: Current Perspectives
por: Murthy, Hemant, et al.
Publicado: (2019)

The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer
por: Choi, Ji-Young, et al.
Publicado: (2023)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h2jjh05j215btc8il97gkofvn1